|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase I Study to Determine the Maximum Tolerated Dose and Evaluate Safety, Tolerability, and Pharmacokinetics of NM6603 in Patients With Advanced Solid Tumors
This study is to assess the MTD and RP2D of NM6603 in adult patients with advanced solid tumors.
100 Clinical Results associated with Tengji (Xiamen) Biomedical Technology Co., Ltd.
0 Patents (Medical) associated with Tengji (Xiamen) Biomedical Technology Co., Ltd.
100 Deals associated with Tengji (Xiamen) Biomedical Technology Co., Ltd.
100 Translational Medicine associated with Tengji (Xiamen) Biomedical Technology Co., Ltd.